title: Diabetes therapy and cancer risk: where do we stand when treating patients?
abstract: The pathophysiology of type 2 diabetes mellitus conveys increased cancer risk, and any antidiabetic drug may alter that risk in a favorable or unfavorable way. This article discusses the links between diabetes and cancer, the different agents available for treating diabetes, and the cancer risk associated with these therapies.
authors.affiliation: Department of Medicine, Section of Endocrinology & Metabolism, Assistant Professor of Medicine, Louisiana State University Health Sciences Center, Shreveport gsun1@lsuhsc.edu.
authors.forename: Grace E
authors.initials: GE
authors.lastname: Ching Sun
authors.affiliation: Endocrinology and Metabolism Institute, Cleveland Clinic; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
authors.forename: Sangeeta R
authors.initials: SR
authors.lastname: Kashyap
authors.affiliation: Endocrinology and Metabolism Institute, Cleveland Clinic.
authors.forename: Christian
authors.initials: C
authors.lastname: Nasr
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D055088:Early Detection of Cancer / Q000379:methods; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000145:classification; D009369:Neoplasms / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents